Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
National Cancer Institute, Naples
This study is for patients with previously diagnosed advanced non small cell lung cancer (NSCLC, stage IIIb or IV) who had progression of their disease during or after first-line therapy containing platinum. Patients will be assigned to receive 6 cycles of therapy from one of four treatment regimens:
* docetaxel
* docetaxel + vinorelbine
* docetaxel + gemcitabine
* docetaxel + capecitabine
Age
0–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Written informed consent
Age \> 18
Histological diagnosis of non small-cell lung cancer (NSCLC)
Stage IIIb or Stage IV disease (in IIIb, previous treatment with chemotherapy + radiotherapy, or metastatic supraclavicular lymph nodes or pleural effusion)
Disease in progression
Previous chemotherapy with platinum-derivative (and with \> 21 days from last administration)
You may not be if
ECOG performance status \> 2
Age \> 75 years
History of malignant neoplasm within the previous 5 years (except for baso- or spino-cellular skin carcinoma and in-situ carcinoma of the uterine cervix, provided they are being adequately treated)
